Skip to main content
All inhalers

QVAR REDIHALER

Beclomethasone

QVAR REDIHALER

ICS MDI

Beclomethasone dipropionate · Teva Pharmaceuticals

Clinical Reference

Active Medication & Mechanism

  • Beclomethasone dipropionate ICS
    40 mcg or 80 mcg per actuation

    Pro-drug ICS that is converted to active metabolite beclomethasone-17-monopropionate (17-BMP) in the lungs. Provides potent anti-inflammatory activity, reducing inflammatory cells and mediators in the airways. HFA formulation delivers extrafine particles for enhanced small airway deposition.

FDA-Approved Dosing by Indication

// approval varies by strength + age
Asthma
3/4 approved regimens
  • 40 mcg FDA Approved
    Pop · Patients ≥12 years (previously on bronchodilators alone)
    1 inhalation twice daily
    Starting dose for patients on bronchodilators alone.
    Total · 80 mcg
  • 80 mcg FDA Approved
    Pop · Patients ≥12 years (previously on ICS)
    1 inhalation twice daily
    For patients previously on ICS. Maximum dose: 320 mcg/day.
    Total · 160 mcg
  • 80 mcg FDA Approved
    Pop · Patients ≥12 years (previously on oral steroids)
    2 inhalations twice daily
    Maximum recommended dose.
    Total · 320 mcg
  • Any strength Not Approved
    Pop · Acute bronchospasm
    Total · Not a bronchodilator. Not for acute bronchospasm. Use a SABA.
Acute Use
0/1 approved regimens
  • Any strength Not Approved
    Pop · Acute bronchospasm / rescue
    Total · Not for acute use. Use a SABA.

For clinical reference only. This workspace is intended for use by qualified healthcare professionals and is not a substitute for clinical judgement, prescribing information, or product monographs. Always verify doses and indications against the most current labelling before prescribing.

Inhaler Database · © inhalerdatabase.com 2024–2026 — All rights reserved